Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)

Published:2008-09 Issue:3 Volume:61 Page:405-415
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Carlson Josh J.,Reyes Carolina,Oestreicher Nina,Lubeck Deborah,Ramsey Scott D.,Veenstra David L.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference50 articles.

1. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007.

2. The burden of illness of cancer: economic cost and quality of life;Brown;Annu Rev Public Health,2001

3. NICE. ERG report: erlotinib for the treatment of relapsed non-small cell lung cancer. Liverpool: The National Institute for Health and Clinical Excellence; 2006.

4. NCCN. NCCN Clinical practice guidelines in oncology: non-small cell lung cancer V.2.2006; 2006.

5. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-02-22

A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation

;Cancer Management and Research;2020-06

3. A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer;Clinical Drug Investigation;2019-10-03

4. Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review;PharmacoEconomics;2019-05-13

5. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China;PLOS ONE;2018-10-23